Please login to the form below
SGLT2 inhibitors
This page shows the latest SGLT2 inhibitors news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca’s Farxiga shows benefits for heart failure patients in phase 3 trial
DELIVER was an international, randomised, double-blind phase 3 trial evaluating the efficacy of the SGLT2 inhibitor, compared with placebo, in the treatment of heart failure patients with left ventricular ejection ... of SGLT2 inhibitors in this group,
Latest news
-
Lexicon Pharma announces strong CV data for first-in-class sotagliflozin at the European Society of Cardiology’s annual meeting
of clinical data from selective SGLT2 inhibitors.”. ... They are responsible for glucose absorption in the gastrointestinal tract (SGLT1) and the kidney (SGLT2).
-
AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients
SGLT2 inhibitor failed to significantly reduce the number of patients who experienced organ failure or died compared to placebo. ... SGLT2 inhibitors – such as Farxiga (dapagliflozin) – can be used to provide organ protection for patients with
-
Merck, Bayer flesh out vericiguat heart failure data at ACC
Some outstanding questions include where vericiguat lies in relation to the SGLT2 inhibitors such as Boehringer Ingelheim/Eli Lilly’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga/Forxiga (dapagliflozin), which are also ... Here too the SGLT2
-
FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes
There are around 40, 000 new type 1 diabetics diagnosed in the US every year, and at the moment no SGLT2 inhibitors have been approved for adjunctive use with insulin. ... It also turned down Lexicon Pharma and Sanofi’s SGLT2 inhibitor Zynquista
-
Trial of Amgen, Servier’s heart failure drug clears interim check
Other drugs in the SGLT2 class – including Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) – are also being tested in heart failure indications. ... GlobalData expects the SGLT2 inhibitors in particular to stimulate strong growth in
More from news
Approximately 5 fully matching, plus 40 partially matching documents found.
Latest Intelligence
-
Back to the future
The introduction of a wave of SGLT2 inhibitors will further energise the market - with Novo Nordisk, J&J, Lily, Boehringer, AZ, Merck and Pfizer all due to compete in this space.
-
Interview: Christopher Boulton, AstraZeneca
the way SGLT2 inhibitors work by reducing the amount of glucose absorbed in the kidney and passing it out through urine. ... Forxiga is set to face competition from other SGLT2 inhibitors either recently approved or on the horizon, including
-
Pharma deals during April 2013
SGLT2 inhibitors block the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels. ... Clearly the pressure is on, the announcement coming only a month after Johnson &Johnson obtained US approval for its
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- How an AI algorithm might save your life
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
